Ultima Genomics to provide low-cost $100 genome sequencing

Pan-cancer proteogenomics reveals potential drug targets

Researchers at Baylor College of Medicine and collaborating institutions have uncovered new potential therapeutic targets for cancer and new insights into existing cancer drug targets.

June 28, 2024

Vol.50 No.26

Clinical Trials & Tribulations

Paired tumor-germline testing can enhance patient care—with guidance from genetics specialists

In May, the American Society of Clinical Oncology released guidelines on the use of germline genetic testing panels in concert with tumor testing for cancer patients. xxx:more

Decoding the genes behind dolastatin 10 paves the way for new cancer therapeutics

University of Florida College of Pharmacy researchers have pinpointed the genetic blueprints behind dolastatin 10, a marine natural product that has led to six FDA-approved cancer drugs since 2011.

February 16, 2024

Vol.50 No.07

Letter To The Editor

The field of population epigenetics is failing on rigor and reproducibility

To the editor, I was not booed off the stage. Rather, the response was incredibly enthusiastic. After my session people lined up for over 45 minutes to talk to me. Many thanked me for publicizing this issue, indicating that the problems with the Illumina platform have been apparent to many, but no one else was...

December 08, 2023

Vol.49 No.45

In Brief

Eric Kmiec named editor in chief of Gene and Genome Editing

Eric Kmiec, executive director and chief scientific officer of ChristianaCare’s Gene Editing Institute, has been selected as editor-in-chief of the scientific journal Gene and Genome Editing. Kmiec previously served three years on the journal’s board.

September 15, 2023

Vol.49 No.34

Clinical Roundup

NIH unveils comprehensive dataset to enable analysis of genomic, proteomic, and clinical data

NIH is planning to release a comprehensive dataset that standardizes genomic, proteomic, imaging, and clinical data from individual studies of more than 1,000 tumors across 10 cancer types.

September 08, 2023

Vol.49 No.33

Ultima Genomics to provide low-cost $100 genome sequencing

YOU MAY BE INTERESTED IN

Pan-cancer proteogenomics reveals potential drug targets

Paired tumor-germline testing can enhance patient care—with guidance from genetics specialists

Decoding the genes behind dolastatin 10 paves the way for new cancer therapeutics

The field of population epigenetics is failing on rigor and reproducibility

Eric Kmiec named editor in chief of Gene and Genome Editing

NIH unveils comprehensive dataset to enable analysis of genomic, proteomic, and clinical data

Renew today!

Subscriber content

Login